Kruppel-Like Transcription Factor-4 Gene Expression and DNA Methylation Status in Type 2 Diabetes and Diabetic Nephropathy Patients
Copyright © 2019 IMSS. Published by Elsevier Inc. All rights reserved..
BACKGROUND/AIM: Diabetic nephropathy (DN) is one of the most serious microvascular complications in diabetic patients. The kruppel-like transcription factor-4 (KLF-4) affects the expression of genes involved in the pathogenesis of DN. The present study aims to identify the KLF-4 expression and DNA methylation (DNAMe) status in patients with type-2 diabetes (T2D) and DN and to reveal the contribution of the KLF-4 to the development of DN.
MATERIAL AND METHODS: The cohort study was performed with blood samples from 120 individuals; T2D group (n = 40), DN group (n = 40) and control group (n = 40). The expression level of the KLF-4 gene was analyzed using the real-time polymerase chain reaction (qRT-PCR) and the methylation profile detected using the methylation-specific PCR (MS-PCR) technique.
RESULTS: According to our findings, KLF-4 mRNA expression in the T2D group was 1.60 fold lower than in the control group (p = 0.001). In the DN group, the expression of KLF-4 mRNA was 2.92-fold less than that of the T2D group (p = 0.001). There was no significant alteration in the DNAMe status among the groups.
CONCLUSION: Our findings showed that regardless of the DNAMe status, KLF-4 gene expression may play a role in the development of T2D and DN. This suggests that the KLF-4 gene may be the target gene in understanding the mechanism of nephropathy, which is the most important complication of diabetes, and planning nephropathy-related treatments, but the data should be supported with more studies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:50 |
|---|---|
| Enthalten in: |
Archives of medical research - 50(2019), 3 vom: 26. Apr., Seite 91-97 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Coskun, Zeynep Mine [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.02.2020 Date Revised 04.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.arcmed.2019.05.012 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM301043175 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM301043175 | ||
| 003 | DE-627 | ||
| 005 | 20231225103818.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.arcmed.2019.05.012 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1003.xml |
| 035 | |a (DE-627)NLM301043175 | ||
| 035 | |a (NLM)31495395 | ||
| 035 | |a (PII)S0188-4409(19)30091-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Coskun, Zeynep Mine |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Kruppel-Like Transcription Factor-4 Gene Expression and DNA Methylation Status in Type 2 Diabetes and Diabetic Nephropathy Patients |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.02.2020 | ||
| 500 | |a Date Revised 04.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019 IMSS. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND/AIM: Diabetic nephropathy (DN) is one of the most serious microvascular complications in diabetic patients. The kruppel-like transcription factor-4 (KLF-4) affects the expression of genes involved in the pathogenesis of DN. The present study aims to identify the KLF-4 expression and DNA methylation (DNAMe) status in patients with type-2 diabetes (T2D) and DN and to reveal the contribution of the KLF-4 to the development of DN | ||
| 520 | |a MATERIAL AND METHODS: The cohort study was performed with blood samples from 120 individuals; T2D group (n = 40), DN group (n = 40) and control group (n = 40). The expression level of the KLF-4 gene was analyzed using the real-time polymerase chain reaction (qRT-PCR) and the methylation profile detected using the methylation-specific PCR (MS-PCR) technique | ||
| 520 | |a RESULTS: According to our findings, KLF-4 mRNA expression in the T2D group was 1.60 fold lower than in the control group (p = 0.001). In the DN group, the expression of KLF-4 mRNA was 2.92-fold less than that of the T2D group (p = 0.001). There was no significant alteration in the DNAMe status among the groups | ||
| 520 | |a CONCLUSION: Our findings showed that regardless of the DNAMe status, KLF-4 gene expression may play a role in the development of T2D and DN. This suggests that the KLF-4 gene may be the target gene in understanding the mechanism of nephropathy, which is the most important complication of diabetes, and planning nephropathy-related treatments, but the data should be supported with more studies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a DNA methylation | |
| 650 | 4 | |a Diabetic nephropathy | |
| 650 | 4 | |a Epigenetics | |
| 650 | 4 | |a Kruppel-like transcription factor-4 | |
| 650 | 4 | |a Type 2 diabetes | |
| 650 | 7 | |a KLF4 protein, human |2 NLM | |
| 650 | 7 | |a Kruppel-Like Factor 4 |2 NLM | |
| 650 | 7 | |a Kruppel-Like Transcription Factors |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 700 | 1 | |a Ersoz, Melike |e verfasserin |4 aut | |
| 700 | 1 | |a Adas, Mine |e verfasserin |4 aut | |
| 700 | 1 | |a Hancer, Veysel Sabri |e verfasserin |4 aut | |
| 700 | 1 | |a Boysan, Serife Nur |e verfasserin |4 aut | |
| 700 | 1 | |a Gonen, Mustafa Sait |e verfasserin |4 aut | |
| 700 | 1 | |a Acar, Aynur |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Archives of medical research |d 1996 |g 50(2019), 3 vom: 26. Apr., Seite 91-97 |w (DE-627)NLM012656291 |x 1873-5487 |7 nnns |
| 773 | 1 | 8 | |g volume:50 |g year:2019 |g number:3 |g day:26 |g month:04 |g pages:91-97 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.arcmed.2019.05.012 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 50 |j 2019 |e 3 |b 26 |c 04 |h 91-97 | ||